

## **Commercial/Healthcare Exchange PA Criteria**

Effective: June 2007

#### Prior Authorization: Cesamet

**Products Affected:** Cesamet (nabilone) oral capsules

*Medication Description:* Cesamet (nabilone) is a synthetic cannabinoid for oral administration. Antiemetic activity may be due to effect on cannabinoid receptors (CB1) within the central nervous system.

*Covered Uses:* Treatment of the nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments.

### Exclusion Criteria:

- 1. Patients who has a history of hypersensitivity to any cannabinoid.
- 2. Use of Cesamet on as needed basis or as a first antiemetic product prescribed for a patient.

#### **Required Medical Information:**

- 1. Diagnosis
- 2. History of previous medications tried/failed

#### Age Restrictions: N/A

#### Prescriber Restrictions: N/A

#### Coverage Duration: 3 months

#### **Other Criteria:**

- A. Patient is being treated for nausea and vomiting associated with cancer chemotherapy; AND
- B. Patient has an intolerance to, or treatment failure of at least TWO previous antiemetic therapies, one of which must be a serotonin 5HT3 antagonist (i.e. ondansetron).

#### **<u>References</u>**:

1. Cesamet prescribing information Valeant Pharmaceuticals International Costa Mesa, CA



# ConnectiCare.

**Policy Revision history** 

Rev #	Type of Change	Summary of Change	Sections Affected	Date
1	New Policy	New Policy	All	June 2007
2		Updated Template from CCI to EH Updated exclusion criteria in the FDA labeled contraindications: Patients who has a history of hypersensitivity to any cannabinoid, Use of Cesamet on as needed basis or as a first antiemetic product prescribed for a patient.		2/4/2020

